
Anne Wojcicki to Reacquire 23andMe and Its Data in $305 Million Deal
23andMe’s Revival: Anne Wojcicki’s Strategic Reclamation Navigating Turbulence in a Genetic Testing Titan The rollercoaster journey of 23andMe, a pioneer in direct-to-consumer genetic testing, encapsulates the volatility inherent in fast-evolving biotech enterprises. Once valued at a staggering $6 billion, the company’s sharp descent to a $305 million bankruptcy sale reveals a complex interplay of operational…